Samsara BioCapital is a new breed of biotech investment fund focused on translating cutting-edge biology into new therapies to treat patients with unmet medical needs. Founded in 2016 by Srinivas Akkaraju, MD, PhD, our team of scientists, investors, and entrepreneurs takes a long-term view to value creation across all stages of public and private life science companies. We believe in a collaborative, hands-on approach, working closely with entrepreneurs to harness exciting scientific advances and build leading companies. Samsara actively manages approximately US$410 million in assets on behalf of endowments, foundations, and family offices. For more information, visit www.samsaracap.com.
Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 3,000 employees provide the highest quality stand-alone and integrated drug discovery and development solutions from target to clinic. For additional information, please go to www.evotec.com.
KCK, Ltd. is a single-family, evergreen fund with offices in the SF Bay Area and New York City. We invest across a broad range of sectors and in companies of all stages in the US, Europe and Emerging Markets, including in biotech, industrials, deep tech, med tech and financial services. Our investments are flexible and long-term, with a unique focus on technically and scientifically challenging projects.
